Patents by Inventor Andrew Mercer

Andrew Mercer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250001006
    Abstract: The present invention relates to recombinant adeno-associated viruses (rAAVs) having capsid proteins engineered to be a tropic or have limited tropism which may be further engineered by insertion of a targeting domains that confer and/or enhance desired properties, particularly increased transduction in CNS or muscle cells or other target tissue relative to a rAAV having a reference capsid.
    Type: Application
    Filed: October 7, 2022
    Publication date: January 2, 2025
    Inventors: Olivier Danos, Samantha Yost, Andrew Mercer, Ye Liu, Joseph Bruder, Subha Karumuthil-Melethil, Elad Firnberg, Randolph Qian, April R. Tepe, Jennifer M. Egley
  • Publication number: 20240417737
    Abstract: Disclosed are methods and compositions relating to antisense therapy for treating epilepsy, such as a temporal lobe epilepsy, in a subject in need thereof by targeting Grik2 mRNA. In particular, the disclosure provides inhibitory RNA constructs capable of inhibiting expression of GluK2 protein and inhibiting epileptiform discharges in hyperexcitable neuronal circuits.
    Type: Application
    Filed: May 16, 2022
    Publication date: December 19, 2024
    Inventors: Chenxia HE, Richard PORTER, Andrew MERCER, Olivier DANOS, April R. TEPE
  • Publication number: 20240218397
    Abstract: The present invention relates to nucleic acid expression cassettes that are engineered to include polynucleotide sequences useful as inert stuffer (or filler) sequences in expression cassettes, particularly useful for transgene expression delivered as viral vectors, incorporating the engineered expression cassettes described herein, including rAA Vs, for use in therapy.
    Type: Application
    Filed: May 3, 2022
    Publication date: July 4, 2024
    Inventors: Ye LIU, Andrew MERCER, Chunping QIAO, April R. TEPE, Nicolas BUSS
  • Publication number: 20240018524
    Abstract: The present disclosure provides methods and compositions relating to gene therapy for treating epilepsy, such as a temporal lobe epilepsy, in a subject in need thereof by targeting Grik2 mRNA. In particular, the present disclosure provides inhibitory RNA constructs capable of inhibiting expression of GluK2 protein and inhibiting epileptiform discharges in hyperexcitable neuronal circuit.
    Type: Application
    Filed: July 9, 2021
    Publication date: January 18, 2024
    Inventors: Valérie CREPEL, Christophe MULLE, Céline BOILEAU, Séverine DEFORGES, Olivier DANOS, Andrew MERCER, Richard PORTER, April R. TEPE
  • Publication number: 20230381341
    Abstract: The present invention relates to recombinant adeno-associated viruses (rAAVs) having capsid proteins that have a tropism for ocular tissue. The rAAVs have capsids that have enhanced or increased transduction of ocular tissues as compared to reference rAAVs. Such rAAVs may be useful in delivering transgenes encoding therapeutic proteins for the treatment of ocular disease.
    Type: Application
    Filed: October 7, 2021
    Publication date: November 30, 2023
    Inventors: Joseph Bruder, Xu Wang, Wei-Hua Lee, Elad Firnberg, Samantha Yost, Andrew Mercer, Ye Liu, Olivier Danos, April R. Tepe
  • Publication number: 20230374541
    Abstract: The present invention relates to recombinant adeno-associated viruses (rAAVs) having capsid proteins engineered to include amino acid sequences and/or amino acid substitutions that confer and/or enhance desired properties, particularly increased transduction in CNS or muscle cells relative to a rAAV having a reference capsid.
    Type: Application
    Filed: October 7, 2021
    Publication date: November 23, 2023
    Inventors: Olivier Danos, Samantha Yost, Andrew Mercer, Ye Liu, Joseph Bruder, Subha Karumuthil-Melethil, Elad Firnberg, Randolph Qian, April R. Tepe, Jennifer M. Egley
  • Publication number: 20230323366
    Abstract: The present disclosure relates to gene therapy targeting GluK2 subunit that can be used to inhibit epileptiform discharges. Short interfering RNA sequences against the human Grik2 gene sequence are described which are efficient in decreasing the expression of GluK2-containing KARs in neurons engineered to express the equivalent shRNA or miRNA. Using a tissue culture model of TLE, the examples remarkably demonstrate that viral expression of shRNA or miRNA inhibits the frequency of epileptiform discharges. Therefore, RNA therapeutics aimed at decreasing the expression of GluK2-containing KARs in neurons can remarkably prevent spontaneous epileptiform discharges in TLE. In particular, the present disclosure relates to a recombinant antisense oligonucleotide that targets a Grik2 mRNA.
    Type: Application
    Filed: July 9, 2021
    Publication date: October 12, 2023
    Inventors: Céline BOILEAU, Valérie CREPEL, Séverine DEFORGES, Julie MASANTE, Christophe NULLE, Angélique PERET, Olivier DANOS, Andrew MERCER
  • Publication number: 20230304022
    Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.
    Type: Application
    Filed: September 23, 2022
    Publication date: September 28, 2023
    Inventors: Carlos F. Barbas, III, Andrew Mercer, Brian M. Lamb, Thomas Gaj
  • Publication number: 20230227829
    Abstract: The present disclosure provides methods and compositions relating to gene therapy for treating epilepsy, such as a temporal lobe epilepsy, in a subject in need thereof by targeting Grik2 mRNA. In particular, the present disclosure provides inhibitory RNA constructs capable of inhibiting expression of GluK2 protein and inhibiting epileptiform discharges in hyperexcitable neuronal circuit.
    Type: Application
    Filed: January 13, 2023
    Publication date: July 20, 2023
    Inventors: Valérie CREPEL, Christophe MULLE, Céline BOILEAU, Séverine DEFORGES, Olivier DANOS, Andrew MERCER, Richard PORTER, April R. TEPE
  • Publication number: 20230039652
    Abstract: The present disclosure relates to gene therapy targeting GluK2 subunit that can be used to inhibit epileptiform discharges. Short interfering RNA sequences against the human Grik2 gene sequence are described which are efficient in decreasing the expression of GluK2-containing KARs in neurons engineered to express the equivalent shRNA or miRNA. Using a tissue culture model of TLE, the examples remarkably demonstrate that viral expression of shRNA or miRNA inhibits the frequency of epileptiform discharges. Therefore, RNA therapeutics aimed at decreasing the expression of GluK2-containing KARs in neurons can remarkably prevent spontaneous epileptiform discharges in TLE. In particular, the present disclosure relates to a recombinant antisense oligonucleotide that targets a Grik2 mRNA.
    Type: Application
    Filed: June 30, 2022
    Publication date: February 9, 2023
    Inventors: Valérie CREPEL, Christophe Mulle, Céline Boileau, Julie Masante, Séverine Deforges, Angélique Peret, Olivier Danos, Andrew Mercer
  • Patent number: 11466277
    Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: October 11, 2022
    Assignee: The Scripps Research Institute
    Inventors: Carlos F. Barbas, Andrew Mercer, Brian M. Lamb, Thomas Gaj
  • Publication number: 20220251567
    Abstract: The present disclosure relates to gene therapy targeting GluK2 subunit that can be used to inhibit epileptiform discharges. Short interfering RNA sequences against the human Grik2 gene sequence are described which are efficient in decreasing the expression of GluK2-containing KARs in neurons engineered to express the equivalent shRNA or miRNA. Using a tissue culture model of TLE, the examples remarkably demonstrate that viral expression of shRNA or miRNA inhibits the frequency of epileptiform discharges. Therefore, RNA therapeutics aimed at decreasing the expression of GluK2-containing KARs in neurons can remarkably prevent spontaneous epileptiform discharges in TLE. In particular, the present disclosure relates to a recombinant antisense oligonucleotide that targets a Grik2 mRNA.
    Type: Application
    Filed: July 10, 2020
    Publication date: August 11, 2022
    Inventors: Valérie CREPEL, Christophe MULLE, Céline BOILEAU, Julie MASANTE, Séverine DEFORGES, Angélique PERET, Olivier DANOS, Andrew MERCER
  • Publication number: 20220186256
    Abstract: The present invention relates to recombinant adeno-associated viruses (rAAVs) having capsid proteins engineered to include amino acid sequences that confer and/or enhance desired properties. In particular, the invention provides engineered capsid proteins comprising peptide insertions from heterologous proteins inserted within or near variable region IV (VR-IV) of the virus capsid, such that the insertion is surface exposed on the AAV particle. The invention also provides capsid proteins that direct rAAVs to target tissues, in particular, capsid proteins comprising peptides derived from erythropoietin or dynein that are inserted into surface-exposed variable regions and that target rAAVs to retinal tissue and/or neural tissue, including the central nervous system, and deliver therapeutics for treating neurological and/or eye disorders.
    Type: Application
    Filed: April 2, 2020
    Publication date: June 16, 2022
    Inventors: Olivier Danos, Ye Liu, Andrew Mercer, Samantha Yost, Subha Karumuthil-Melethil, Elad Firnberg
  • Publication number: 20210147854
    Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.
    Type: Application
    Filed: September 24, 2020
    Publication date: May 20, 2021
    Inventors: Carlos F. Barbas, Andrew Mercer, Brian M. Lamb, Thomas Gaj
  • Patent number: 10829766
    Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: November 10, 2020
    Assignee: The Scripps Research Institute
    Inventors: Carlos F. Barbas, III, Andrew Mercer, Brian M. Lamb, Thomas Gaj
  • Publication number: 20180230474
    Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.
    Type: Application
    Filed: January 23, 2018
    Publication date: August 16, 2018
    Inventors: Carlos F. Barbas, III, Andrew Mercer, Brian M. Lamb, Thomas Gaj
  • Patent number: 9902962
    Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques. The invention provides a chimeric polypeptide. The polypeptide includes: a) a recombinase, nuclease or transcription factor, or fragment thereof; and b) a transcription activator-like effector (TALE) protein.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: February 27, 2018
    Assignee: The Scripps Research Institute
    Inventors: Carlos F. Barbas, III, Andrew Mercer, Brian M. Lamb, Thomas Gaj
  • Publication number: 20150284728
    Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques. The invention provides a chimeric polypeptide. The polypeptide includes: a) a recombinase, nuclease or transcription factor, or fragment thereof; and b) a transcription activator-like effector (TALE) protein.
    Type: Application
    Filed: September 4, 2013
    Publication date: October 8, 2015
    Inventors: Carlos F. Barbas, III, Andrew Mercer, Brian M. Lamb, Thomas Gaj
  • Patent number: 9075694
    Abstract: Automating processes in an automation platform. Specifying a program that when executed by the platform implements the process. The program including process description, process components. The description including component initialization instructions having input parameter(s) and initialized component execution instructions having an execution state. Components having an initialization interface, an execution interface, and at least one of simulation instructions and operation instructions. Components characterized by output parameters, and operative upon receiving input parameters via the initialization interface to initialize the component. Initialized components operative upon receiving an execution state via the execution interface to execute the initialized component in accordance with the execution state, and in absence of operation instructions, to return a simulated output in the format of the output parameters in accordance with the simulation instructions.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: July 7, 2015
    Inventors: Shane Andrew Mercer, John Matthew Martin, Lindsay Ian Smith
  • Publication number: 20130097096
    Abstract: Implementing a process in an automation platform. Representing conceptual entities of the process as a nodes in a conceptual graph. Representing process relationships between the conceptual entities as edges between the nodes of the conceptual graph. Transforming the conceptual graph into a structural graph representing an automation design of the process. Transforming the structural graph into implementation artifacts executable on the automation platform. Entities can represent a feature, a constraint, a project phase, a screen, a data item, and a process description. Relationships can include a dependency relationship, a temporal relation-ship, and a parent-child relationship. The transformation into a structural graph being traceable between elements of the conceptual graph and the structural graph. The transformation into a structural graph controlled by a first configuration information. The transformation into a implementation artifacts controlled by a second configuration information.
    Type: Application
    Filed: April 27, 2011
    Publication date: April 18, 2013
    Applicant: CORE TECHNOLOGY LIMITED
    Inventors: Shane Andrew Mercer, John Matthew Martin, Lindsay Ian Smith